The UK Competition and Markets Authority (CMA), the UK competition regulator, continues to be particularly active in the pharmaceutical sector. Several findings of anticompetitive conduct by various companies in recent years ultimately led to parliament tightening pricing controls on medicines sold to the NHS. However, with some important CMA decisions having recently been overturned on appeal, question marks have arisen over its future enforcement approach. Charles Livingstone and Adam McCabe from Brodies' Government, Regulation and Competition team provided a snapshot of the key issues for Pharma Times this month, which can be viewed here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.